Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Chance Pharma Acquires China Rights for Inhaled Parkinson’s Therapy in $144 Million Deal

publication date: May 10, 2023

Hangzhou Chance Pharma entered a deal worth up to $144 million to commercialize Acorda’s inhaled therapy for Parkinson’s disease in Greater China. In the US, Inbrija is approved as an intermittent treatment for episodic motor fluctuations (OFF episodes) in adult Parkinson's disease patients who are being treated with a levodopa/dopa-decarboxylase inhibitor. Chance, which will be responsible for China regulatory approval, will make up-front and milestone payments of $11.5 million plus up to $132.5 million in sales milestones. China has the world’s largest population of patients with Parkinson’s. More details....

See our other articles on Chance.


Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here